Focused On-demand Library for tRNA-specific adenosine deaminase 2

Details

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

PARTNER
Receptor.AI
 
UPACC
Q7Z6V5

UPID:
ADAT2_HUMAN

ALTERNATIVE NAMES:
Deaminase domain-containing protein 1; tRNA-specific adenosine-34 deaminase subunit ADAT2

ALTERNATIVE UPACC:
Q7Z6V5; A6NL12; B3KWY3; Q7Z327; Q8IY39

BACKGROUND:
The protein known as tRNA-specific adenosine deaminase 2, with alternative names Deaminase domain-containing protein 1 and ADAT2, is essential for the deamination of adenosine-34 to inosine in tRNAs. This process is critical for accurate protein synthesis and genetic code translation.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of tRNA-specific adenosine deaminase 2 offers a promising avenue for developing novel therapeutic approaches. Its key role in the fidelity of protein synthesis highlights its potential impact on understanding and treating diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.